Stoke Therapeutics (STOK) director granted options to buy 17,786 shares

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reported that director Edward M. Kaye, MD received a grant of options to acquire 17,786 shares of Common Stock. The options have an exercise price of $29.46 per share and expire on June 2, 2036.

According to the terms, the option vests in full on the earlier of June 3, 2027 or the date of the company’s next annual stockholder meeting, subject to his continued service with the company through that vesting date. This is a compensation-related award rather than an open-market stock purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaye Edward M. MD

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	17,786	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 17,786 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 17,786 shares Exercise price: $29.46 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 17,786 shares Director stock option award

Exercise price $29.46 per share Stock option strike price

Expiration date June 2, 2036 Option term end

Post-grant holdings 17,786 options Total derivative holdings after transaction

Vesting date Earlier of June 3, 2027 or next annual meeting Full vesting trigger, service-based

Key Terms

Director Stock Option, exercise price, expiration date, vest in full, +1 more

5 terms

Director Stock Option financial

"security_title: Director Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 29.4600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-02T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in full financial

"The option shall vest in full on the earlier of: (i) June 3, 2027"

annual meeting financial

"or (ii) the date of the issuer's next annual meeting of its stockholders"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$29.46	06/03/2026		A		17,786		(1)	06/02/2036	Common Stock	17,786	$0	17,786	D

Explanation of Responses:

1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Edward M. Kaye report at Stoke Therapeutics (STOK)?

Edward M. Kaye reported receiving a grant of stock options to acquire 17,786 shares of Stoke Therapeutics Common Stock. These options are a director compensation award, not an open-market purchase, and were reported on a Form 4 insider filing.

How many Stoke Therapeutics (STOK) shares can Edward Kaye buy under the new options?

The new option grant allows Edward Kaye to acquire 17,786 shares of Stoke Therapeutics Common Stock. This entire amount is subject to vesting conditions before it becomes exercisable, tying the potential ownership to his continued service as a director.

What is the exercise price and expiration date of Edward Kaye’s STOK options?

The options carry an exercise price of $29.46 per share and expire on June 2, 2036. This means Kaye can buy shares at $29.46 any time after vesting and before the June 2036 expiration, subject to plan and agreement terms.

When do Edward Kaye’s Stoke Therapeutics (STOK) options vest?

The option vests in full on the earlier of June 3, 2027, or the date of Stoke Therapeutics’ next annual stockholder meeting. Vesting is also conditioned on Kaye continuing to serve the company through the applicable vesting date.

Is Edward Kaye’s Form 4 at Stoke Therapeutics (STOK) a stock purchase or a grant?

The Form 4 reflects a grant of stock options, not an open-market stock purchase. The transaction is coded as a grant or award, providing the right to buy 17,786 shares at $29.46 after the options vest and before expiration.

How many options does Edward Kaye hold after this Stoke Therapeutics grant?

After this grant, Edward Kaye holds 17,786 options as reported in the filing. This figure represents his total option holdings reported in this Form 4 and matches the number of shares subject to the newly awarded option.